section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: AORTIC ANEURYSM/DISSECTION

Endo: hyperglycemia, hypoglycemia

GI: liver enzymes, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), diarrhea, nausea, vomiting

MS: arthralgia, myalgia,

tendinitis

,

tendon rupture

Neuro: INTRACRANIAL PRESSURE (INCLUDING PSEUDOTUMOR CEREBRI),

agitation

,

anxiety

,

attention disturbances

,

confusion

,

delirium

,

depression

,

disorientation

,

dizziness

,

hallucinations

, headache,

insomnia

,

memory impairment

,

nightmares

,

paranoia

,

peripheral neuropathy

, SEIZURES, SUICIDAL THOUGHTS/BEHAVIORS,

toxic psychosis

,

tremor

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, AND URTICARIA)

Interactions

Drug-drug:

Availability

Route/Dosage

Acute Bacterial Skin and Skin Structure Infections

Renal Impairment

Community-Acquired Bacterial Pneumonia

Renal Impairment

US Brand Names

Baxdela

Action

  • Inhibits bacterial DNA synthesis by inhibiting DNA gyrase (topoisomerase II) and topoisomerase IV enzymes.
Therapeutic effects:
  • Death of susceptible bacteria.

Spectrum:

Classifications

Therapeutic Classification: anti-infectives

Pharmacologic Classification: Fluoroquinolones

Pharmacokinetics

Absorption: 59% absorbed after oral administration; IV administration results in complete bioavailability.

Distribution: Widely distributed.

Metabolism/Excretion: Primarily undergoes glucuronidation. 50–65% excreted unchanged by the kidneys; 28–48% excreted unchanged in feces.

Half-Life: 3.7 hr (IV); 4.2–8.5 hr (PO).

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POrapid1 hr12 hr
IVrapidend of infusion12 hr

Patient/Family Teaching

Pronunciation

del-a-FLOKS-a-sin

Code

NDC Code